MacroGenics Inc (NASDAQ:MGNX) — Market Cap & Net Worth
Market Cap & Net Worth: MacroGenics Inc (MGNX)
MacroGenics Inc (NASDAQ:MGNX) has a market capitalization of $218.65 Million ($218.65 Million) as of August 9, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16247 globally and #3815 in its home market, demonstrating a 6.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MacroGenics Inc's stock price $4.04 by its total outstanding shares 63560068 (63.56 Million). See how much does MacroGenics Inc reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
MacroGenics Inc Market Cap History: 2015 to 2026
MacroGenics Inc's market capitalization history from 2015 to 2026. Data shows change from $1.97 Billion to $256.78 Million (-16.74% CAGR).
Index Memberships
MacroGenics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.50 Trillion | 0.01% | #444 of 976 |
|
NASDAQ Composite
IXIC
|
$40.86 Trillion | 0.00% | #1594 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.74 Trillion | 0.01% | #223 of 263 |
Weight: MacroGenics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MacroGenics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MacroGenics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.68x
MacroGenics Inc's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.30 Billion | $86.58 Million | -$58.53 Million | 15.01x | N/A |
| 2017 | $1.21 Billion | $155.52 Million | -$19.63 Million | 7.77x | N/A |
| 2018 | $807.21 Million | $60.12 Million | -$171.45 Million | 13.43x | N/A |
| 2019 | $691.53 Million | $62.02 Million | -$151.81 Million | 11.15x | N/A |
| 2020 | $1.45 Billion | $97.76 Million | -$117.78 Million | 14.86x | N/A |
| 2021 | $1.02 Billion | $75.64 Million | -$190.86 Million | 13.49x | N/A |
| 2022 | $426.49 Million | $151.94 Million | -$120.02 Million | 2.81x | N/A |
| 2023 | $611.45 Million | $57.19 Million | -$9.06 Million | 10.69x | N/A |
| 2024 | $206.57 Million | $148.34 Million | -$66.97 Million | 1.39x | N/A |
| 2025 | $102.33 Million | $149.50 Million | -$74.62 Million | 0.68x | N/A |
Competitor Companies of MGNX by Market Capitalization
Companies near MacroGenics Inc in the global market cap rankings as of August 9, 2026.
Key companies related to MacroGenics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #547 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #555 globally with a market cap of $48.81 Billion USD ( ₩72.03 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $496.07 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $784.36 |
| #547 | Argen-X | BR:ARGX | $49.55 Billion | €763.20 |
| #555 | Samsung Biologics Co Ltd | KO:207940 | $48.81 Billion | ₩1556000.00 |
MacroGenics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, MacroGenics Inc's market cap moved from $1.97 Billion to $ 256.78 Million, with a yearly change of -16.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $256.78 Million | +150.93% |
| 2025 | $102.33 Million | -50.46% |
| 2024 | $206.57 Million | -66.22% |
| 2023 | $611.45 Million | +43.37% |
| 2022 | $426.49 Million | -58.19% |
| 2021 | $1.02 Billion | -29.79% |
| 2020 | $1.45 Billion | +110.11% |
| 2019 | $691.53 Million | -14.33% |
| 2018 | $807.21 Million | -33.16% |
| 2017 | $1.21 Billion | -7.05% |
| 2016 | $1.30 Billion | -34.00% |
| 2015 | $1.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 9th, 2026 the market cap of MacroGenics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $218.65 Million USD |
| MoneyControl | $218.65 Million USD |
| MarketWatch | $218.65 Million USD |
| marketcap.company | $218.65 Million USD |
| Reuters | $218.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more